Edition:
United Kingdom

MiMedx Group Inc (MDXG.OQ)

MDXG.OQ on NASDAQ Stock Exchange Capital Market

4.08USD
14 Aug 2018
Change (% chg)

-- (--)
Prev Close
$4.08
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
811,118
52-wk High
$18.24
52-wk Low
$3.01

Latest Key Developments (Source: Significant Developments)

Mimedx Announces Receipt Of Nasdaq Letter
Thursday, 26 Jul 2018 

July 26 (Reuters) - MiMedx Group Inc ::MIMEDX ANNOUNCES RECEIPT OF NASDAQ LETTER.MIMEDX GROUP INC - EXPECTS THAT IT WILL PROVIDE AN UPDATE ONCE NASDAQ HEARINGS PANEL MAKES ITS DETERMINATION FOLLOWING HEARING.MIMEDX GROUP INC - MIMEDX WILL SUBMIT ITS HEARING REQUEST BY JULY 27, 2018.MIMEDX GROUP INC - WILL ALSO REQUEST A FURTHER STAY OF DELISTING, PENDING HEARING.  Full Article

MiMedx Says Pete Petit Resigned As Chairman, CEO
Monday, 2 Jul 2018 

July 2 (Reuters) - MiMedx Group Inc ::MIMEDX ANNOUNCES LEADERSHIP CHANGES AND CORPORATE ACTIONS.MIMEDX GROUP INC - PETE PETIT RESIGNS AS CHAIRMAN AND CHIEF EXECUTIVE OFFICER.MIMEDX GROUP INC - CHARLES EVANS APPOINTED CHAIRMAN OF BOARD.MIMEDX GROUP INC - BILL TAYLOR RESIGNS AS PRESIDENT AND CHIEF OPERATING OFFICER.MIMEDX GROUP INC - DAVID COLES APPOINTED INTERIM CHIEF EXECUTIVE OFFICER.MIMEDX GROUP INC - BOARD OF DIRECTORS HAS COMMENCED A SEARCH TO IDENTIFY AND EVALUATE INTERNAL AND EXTERNAL CANDIDATES TO SERVE AS PERMANENT CEO.MIMEDX GROUP - RESIGNATIONS ARISE, IN PART, FROM INFORMATION AUDIT COMMITTEE IDENTIFIED THROUGH ITS PREVIOUSLY ANNOUNCED INDEPENDENT INVESTIGATION.MIMEDX GROUP INC - COMPANY CONTINUES TO PROVIDE DOCUMENTS IN RESPONSE TO SUBPOENA.MIMEDX GROUP INC - CONDUCTING A FORMAL SEARCH FOR A PERMANENT CHIEF FINANCIAL OFFICER.MIMEDX GROUP INC - IN PARALLEL WITH SEC'S INVESTIGATION, U.S. DEPARTMENT OF JUSTICE IS ALSO REVIEWING THESE MATTERS.MIMEDX GROUP INC - BEGUN TO REVIEW SARBANES-OXLEY AND OTHER INTERNAL CONTROL POLICIES AND PROCEDURES.MIMEDX GROUP INC - STARTED PLANNING PROCESS TO PREPARE RESTATED PRIOR-YEAR FINANCIAL STATEMENTS.MIMEDX GROUP INC - WITHDRAWN ALL PRIOR FINANCIAL GUIDANCE ISSUED FOR 2018.  Full Article

Mimedx Reports Positive Results From Phase 2B Clinical Trial Of Amniofix Injectable
Monday, 26 Mar 2018 

March 26 (Reuters) - Mimedx Group Inc ::MIMEDX REPORTS POSITIVE PAIN AND FOOT FUNCTION RESULTS FROM PHASE 2B CLINICAL TRIAL OF AMNIOFIX® INJECTABLE IN THE TREATMENT OF PLANTAR FASCIITIS.MIMEDX GROUP INC - AMNIOFIX INJECTABLE ACHIEVES PRIMARY AND SECONDARY EFFICACY ENDPOINTS.MIMEDX GROUP INC - ‍STATISTICALLY SIGNIFICANT DIFFERENCE IN PAIN AND FUNCTION COMPARED TO PLACEBO​.  Full Article

Mimedx Comments On Magistrate Recommendation In Co's Lawsuit Against Short Sellers
Thursday, 18 Jan 2018 

Jan 18 (Reuters) - Mimedx Group Inc ::MIMEDX COMMENTS ON MAGISTRATE RECOMMENDATION IN THE COMPANY'S LAWSUIT AGAINST SHORT SELLERS.MIMEDX GROUP INC - "‍BELIEVES THAT MAGISTRATE'S RECOMMENDATIONS ARE IN ERROR, AND THEREFORE MIMEDX WILL BE FILING OBJECTIONS WITH DISTRICT COURT JUDGE​".  Full Article

Mimedx Settles Patent Infringement Lawsuit
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - Mimedx Group Inc ::MIMEDX - SUCCESSFULLY SETTLED CO'S PATENT INFRINGEMENT LAWSUIT AGAINST MUSCULOSKELETAL TRANSPLANT FOUNDATION, MEDLINE INDUSTRIES, LIVENTA BIOSCIENCE.MIMEDX - ‍HAS OBTAINED CONSENT DECREE AND FINAL JUDGMENT ON VALIDITY OF U.S. PATENT NO. 8,709,494​, AND WILL RECEIVE UNDISCLOSED MONETARY SUM.  Full Article

MiMedx Agrees To Lawsuit Settlement With Former Employee
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - MiMedx Group Inc ::MIMEDX AGREES TO LAWSUIT SETTLEMENT WITH FORMER EMPLOYEE.MIMEDX GROUP INC - COMPANY HAS AGREED TO A CONFIDENTIAL LAWSUIT SETTLEMENT FROM ONE FORMER EMPLOYEE.MIMEDX GROUP INC - WILLIAM​ ‍MILLS HAS AGREED NOT TO SELL ANY PRODUCTS OF HIS CURRENT EMPLOYER TO ANY MIMEDX CUSTOMER SERVICED BY MILLS FOR NINE MONTHS.  Full Article

MiMedx Forecasts 2018 Revenue To Be In Range Of $383 Mln To $387 Mln
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - MiMedx Group Inc ::MIMEDX FORECASTS 2018 REVENUE TO BE IN THE RANGE OF $383 MILLION TO $387 MILLION.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $0.45 TO $0.50 EXCLUDING ITEMS.SEES FY 2018 GAAP EARNINGS PER SHARE $0.30 TO $0.35.SEES FY 2018 REVENUE $383 MILLION TO $387 MILLION.FY2018 EARNINGS PER SHARE VIEW $0.43 -- THOMSON REUTERS I/B/E/S.  Full Article

MiMedx Says It Expects To Exceed Top End Of Q4 Revenue Guidance Of $88 Mln
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Mimedx Group Inc ::MIMEDX ANNOUNCES EXPECTATION TO EXCEED TOP END OF FOURTH QUARTER REVENUE GUIDANCE OF $88 MILLION.SEES Q4 2017 REVENUE MORE THAN $88 MILLION.Q4 REVENUE VIEW $88.0 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Mimedx provides update on its reimbursement coverage
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Mimedx Group Inc :Mimedx provides update on its reimbursement coverage.Mimedx Group Inc - ‍provided a reimbursement update in light of FDA final and draft guidance documents related to human tissue​.Mimedx Group Inc - "‍with issuance of final hct/p guidance document by FDA, we believe payer coverage for epifix will further improve"​.  Full Article

MiMedx Group sees FY 2017 revenue $320.6 million to $321.6 million
Friday, 17 Nov 2017 

Nov 17 (Reuters) - MiMedx Group Inc :Sees q4 2017 revenue $87 million to $88 million.Sees FY 2017 revenue $320.6 million to $321.6 million.MiMedx Group Inc - ‍reiterates Q4 and full year 2017 guidance​.FY2017 earnings per share view $0.33, revenue view $321.5 million -- Thomson Reuters I/B/E/S.  Full Article

MiMedx to restate financial statements, replaces CFO

Biotech firm MiMedx Group Inc replaced its chief financial officer on Thursday and said it would restate at least five years of financial statements following an internal investigation into sales and distribution practices, sending shares down as much as 30 percent.